Kiora Pharmaceuticals (NASDAQ:KPRX) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Kiora Pharmaceuticals (NASDAQ:KPRX) in a report published on Tuesday morning,Benzinga reports. The firm currently has a $10.00 target price on the stock.

Separately, Zacks Research downgraded shares of Kiora Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 13th. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $10.00.

Kiora Pharmaceuticals Trading Down 1.8%

NASDAQ KPRX opened at $2.73 on Tuesday. The company’s 50-day moving average price is $2.81 and its 200-day moving average price is $3.01. The stock has a market cap of $9.36 million, a PE ratio of -0.94 and a beta of -0.68. Kiora Pharmaceuticals has a 12 month low of $2.25 and a 12 month high of $4.18.

Kiora Pharmaceuticals (NASDAQ:KPRX) last posted its quarterly earnings results on Friday, August 8th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.04. The company had revenue of $0.75 million for the quarter, compared to the consensus estimate of $0.75 million. As a group, sell-side analysts forecast that Kiora Pharmaceuticals will post 1.28 earnings per share for the current year.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.